EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

01 May 2024 10:03:28 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 Apr 2024 16:26:55 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 Mar 2024 07:15:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 Mar 2024 15:31:01 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 Nov 2023 05:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

08 Nov 2023 16:38:16 By Nasdaq GlobeNewswire

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

30 Oct 2023 15:45:13 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

19 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

02 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

30 Aug 2023 04:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

08 Aug 2023 15:31:58 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

08 Aug 2023 06:15:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

31 Jul 2023 15:05:00 By Nasdaq GlobeNewswire